Stem Cell Transplantation for Newly Diagnosed M/M

 

Stem Cell Transplantation for Newly Diagnosed M/M
18:35

Rush University Medical Center

Upfront Autologous Transplant in Multiple Myeloma

FEATURING Craig Hofmeister
  • 130 views
  • May 27, 2022
  • 1
34:28

2022 Community Oncology Conference

Treatment Conundrums in Myeloma

FEATURING Sergio Giralt
  • 493 views
  • June 7, 2022
  • 4
04:46

ASCO 2022 Conference Coverage

ASCO 2022 on a Post Hoc Analysis of Sustained MRD Negativity From the GRIFFIN Trial: Dara + Len, Bortezomib, and Dex in Transplant-Eligible NDMM

FEATURING Cesar Rodriguez
  • 128 views
  • July 11, 2022
05:24

Luciano Costa

Dara-KRd, Autologous Transplantation, and MRD Response-Adapted Consolidation and Treatment Cessation in NDMM: Final Primary Endpoint Analysis of the MASTER Trial

  • 231 views
  • February 14, 2022
  • 1
07:36

ASCO 2022 Conference Coverage

ASCO 2022 on the Changing Landscape in Post-Transplant Treatment of Newly Diagnosed MM

FEATURING Andrzej Jakubowiak
  • 66 views
  • July 7, 2022
08:09

Krina Patel

What Constitutes a Patient That Is Newly Diagnosed With MM as Eligible for Stem Cell Transplant

  • 281 views
  • September 2, 2021
  • 2
08:41

Parameswaran Hari

The Role of Plerixafor for Stem Cell Mobilization in the Setting of Autologous Stem Cell Transplantation

  • 336 views
  • September 24, 2021
  • 2
05:09

ASCO 2022 Conference Coverage

ASCO 2022 on Myeloma Developing Regimens Using Genomics (MyDRUG) Trial: Results From the RAS Mutation Targeting Arm

FEATURING Shaji Kumar
  • 48 views
  • June 21, 2022
09:32

Christian Chabannon

Stem Cell Mobilization in MM

  • 69 views
  • August 30, 2022
24:19

Dana-Farber Cancer Institute

Phase 3 DETERMINATION Trial: RVd ± ASCT & Lenalidomide Maintenance to Progression in NDMM by Cytogenetic Risk

FEATURING Paul Richardson
  • 376 views
  • September 6, 2022
  • 3
10:29

Mary Kwok

Moving to Quadruplets in NDMM

  • 186 views
  • September 6, 2022
  • 2
05:37

PrecisCa

Induction Therapy for Patients With High-Risk NDMM: When to Utilize Four-Drug Combinations Upfront?

FEATURING Ajay Nooka
  • 65 views
  • September 15, 2022
09:01

Mattia D'Agostino

IMS 2022 on Predictors of Unsustained Negativity in MRD(-) Transplant-Eligible NDMM Pts Enrolled in the FORTE Trial

  • 125 views
  • September 14, 2022
  • 1
13:17

Andrzej Jakubowiak

IMS 2022 ATLAS: A Phase 3 Randomized Trial of Carfilzomib, Lenalidomide, and Dexamethasone vs. Lenalidomide Alone After ASCT for MM

  • 118 views
  • September 21, 2022
09:09

Douglas W. Sborov

IMS 2022 Final Analysis of the GRIFFIN Trial: Daratumumab + Lenalidomide, Bortezomib, & Dexamethasone for Transplant-Eligible NDMM

  • 833 views
  • September 21, 2022
  • 1
15:46

SOHO 2022 Tenth Annual Meeting

SOHO 2022: MM Frontline Therapy for Transplant-Eligible/Ineligible Patients: How to Choose Agents

FEATURING Peter Voorhees
  • 123 views
  • October 14, 2022
07:11

SOHO 2022 Tenth Annual Meeting

SOHO 2022 MM DEBATE: Auto + Maintenance Should Remain SoC in MM

FEATURING Amrita Krishnan
  • 46 views
  • October 14, 2022